{
    "doi": "https://doi.org/10.1182/blood.V106.11.4274.4274",
    "article_title": "Pegfilgrastim Compared to Granulocyte Colony Stimulating Factor (G-CSF) with Hyper-CVAD Chemotherapy Regimen for Aggressive Lymphoid Malignancy. ",
    "article_date": "November 16, 2005",
    "session_type": "Abstracts Not Selected for Presentation",
    "abstract_text": "Aim Pegfilgrastim (Neulasta\u00ae) has proven efficacy as supportive therapy in a variety of chemotherapy regimens, but has not been studied in dose intensive, rapidly cycling regimens such as hyper-CVAD. We examined whether pegfilgrastim leads to similar kinetics of neutrophil recovery as daily G-CSF. Methods Using retrospective analysis, patients receiving pegfilgrastim were matched with controls (G-CSF) for cycle of chemotherapy, prior chemotherapy, dose of cytarabine received, age (60), diagnosis (ALL or NHL) and bone marrow involvement. The primary endpoint was duration of grade IV neutropenia (ANC <500/ul). Secondary endpoints included time to neutrophil recovery, incidence of febrile neutropenia, positive blood cultures and delay in subsequent chemotherapy. Results Between 01/1999 \u2013 06/2005 we identified 124 pegfilgrastim supported cycles in 43 patients. Cases were successfully matched to 124 G-CSF supported cycles from 38 controls. There were no significant differences between cases and controls with regards to prior chemotherapy, age, sex, cytarabine dose, diagnosis or bone marrow involvement. The median duration of grade IV neutropenia was 4 days in both groups (p =0.55).  . Pegfilgrastim (95% CI) . G-CSF controls (95% CI) . P value . Grade IV neutropenia    - All cycles 4 days (0\u201311) 4 days (0\u201310) 0.55 - A cycles 2 days (0\u20137) 2 days (0\u20136) 0.65 - B cycles 6 days (2\u201312) 6 days (0\u201310) 0.70 Time to ANC >500/ul 13 days (10\u201319) 14 days (8\u201318) 0.75 Time to ANC >2000/ul 14 days (11\u201329) 14.5 days (9\u201322) 0.27 Febrile Neutropenia 29% 38% 0.16 Positive Blood Cultures 11% 12% 0.85 Delay in next cycle 44% 47% 0.75 . Pegfilgrastim (95% CI) . G-CSF controls (95% CI) . P value . Grade IV neutropenia    - All cycles 4 days (0\u201311) 4 days (0\u201310) 0.55 - A cycles 2 days (0\u20137) 2 days (0\u20136) 0.65 - B cycles 6 days (2\u201312) 6 days (0\u201310) 0.70 Time to ANC >500/ul 13 days (10\u201319) 14 days (8\u201318) 0.75 Time to ANC >2000/ul 14 days (11\u201329) 14.5 days (9\u201322) 0.27 Febrile Neutropenia 29% 38% 0.16 Positive Blood Cultures 11% 12% 0.85 Delay in next cycle 44% 47% 0.75 View Large Conclusions A single dose of pegfilgrastim is as effective as daily G-CSF for supporting the hyper-CVAD chemotherapy regimen.",
    "topics": [
        "chemotherapy regimen",
        "granulocyte colony-stimulating factor",
        "hypercvad protocol",
        "lymphoid neoplasm, malignant",
        "pegfilgrastim",
        "recombinant granulocyte colony stimulating factor",
        "neutropenia",
        "blood culture",
        "bone marrow involvement",
        "cytarabine"
    ],
    "author_names": [
        "Steven W. Lane, MBBS",
        "Julie Crawford, MBBS",
        "Melita Kenealy, MBBS",
        "Gavin Cull, MBBS",
        "John F. Seymour, MBBS",
        "Miles Prince, MBBS",
        "Paula Marlton, MBBS",
        "Devinder Gill, MBBS",
        "Peter N. Mollee, MBBS MMedSc"
    ],
    "author_dict_list": [
        {
            "author_name": "Steven W. Lane, MBBS",
            "author_affiliations": [
                "Haematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Julie Crawford, MBBS",
            "author_affiliations": [
                "Haematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Melita Kenealy, MBBS",
            "author_affiliations": [
                "Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Gavin Cull, MBBS",
            "author_affiliations": [
                "Haematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "John F. Seymour, MBBS",
            "author_affiliations": [
                "Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Miles Prince, MBBS",
            "author_affiliations": [
                "Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Paula Marlton, MBBS",
            "author_affiliations": [
                "Haematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Devinder Gill, MBBS",
            "author_affiliations": [
                "Haematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Peter N. Mollee, MBBS MMedSc",
            "author_affiliations": [
                "Haematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-04-26T15:44:22",
    "is_scraped": "1"
}